Published in Cancer on April 01, 1981
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate (2010) 1.25
Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol (2010) 1.21
Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol (2008) 0.92
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem (2008) 0.85
Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther (2010) 0.85
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Oncologist (2015) 0.82
Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol (2012) 0.76
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med (1977) 3.38
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Studies on the physiology of protein retention. J Physiol (1931) 2.30
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol (2013) 2.11
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother (1983) 1.93
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
The relationship between the thrombotic and infectious complications of central venous catheters. JAMA (1994) 1.85
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
In vitro studies of cefamandole. Antimicrob Agents Chemother (1976) 1.81
Detection of Serratia outbreaks in hospital. Lancet (1976) 1.81
Comparative in vitro activity of cephalosporins. J Antibiot (Tokyo) (1976) 1.79
Infectious complications of indwelling vascular catheters. Clin Infect Dis (1992) 1.77
Serratia sp. infections in cancer patients. Cancer (1970) 1.73
Comparative in vitro study of temocillin (BRL 17421), a new penicillin. Antimicrob Agents Chemother (1982) 1.73
Is a picture worth a thousand medical words? A randomized trial of reporting formats for medical research data. Methods Inf Med (1991) 1.70
Epidemiological studies of Pseudomonas species in patients with leukemia. Am J Med Sci (1970) 1.70
The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol (1968) 1.69
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med (1989) 1.64
Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study) JPEN J Parenter Enteral Nutr (1994) 1.63
Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med (2000) 1.62
Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood (1977) 1.62
Clinical pharmacology of sisomicin. Antimicrob Agents Chemother (1975) 1.61
Severe tissue trauma triggers the autoimmune state systemic lupus erythematosus in the MRL/++ lupus-prone mouse. Lupus (2009) 1.60
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother (1995) 1.57
Infection in cancer patients. A continuing association. Am J Med (1986) 1.55
Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis (1992) 1.54
Fungal infection and fever of unknown origin in neutropenic patients. Am J Med (1986) 1.54
Mycobacteriosis in patients with malignant disease. Arch Intern Med (1976) 1.54
Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer (1978) 1.53
In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother (1990) 1.52
Hypomagnesemic hypocalcemia secondary to renal magnesium wasting. Ann Intern Med (1975) 1.52
Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis (1983) 1.52
Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol (1990) 1.51
Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother (1989) 1.51
Protothecosis in patients with cancer: case series and literature review. Clin Microbiol Infect (2003) 1.50
Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis (1992) 1.50
A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis (1994) 1.50
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
In vitro susceptibilities of Aeromonas hydrophila against new antibiotics. Antimicrob Agents Chemother (1982) 1.48
Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis (1985) 1.48
In vitro studies of a new semisynthetic penicillin, 6-(d-alpha-sulfoaminophenylacetamido)-penicillanic acid. Appl Microbiol (1969) 1.48
Antibiotics in patients with neutropenia. Arch Intern Med (1984) 1.47
Leukoerythroblastosis. Diagnostic and prognostic significance. Mayo Clin Proc (1974) 1.47